Alexion Pharmaceuticals to acquire Syntimmune for $1.2bn to boost rare disease drug pipeline
In a significant move within the pharmaceutical industry, Alexion Pharmaceuticals, a leading global biopharma company, has announced its acquisition of Syntimmune, a Boston-based clinical-stage biotech ... Read More
Pfizer ends clinical Trials of DMD drug domagrozumab after disappointing results
Pfizer, the US pharmaceutical giant, has announced the discontinuation of two ongoing clinical trials for its drug domagrozumab (PF-06252616), intended to treat Duchenne muscular dystrophy ... Read More
Orchard Therapeutics raises $150m in Series C funding to advance gene therapies for rare diseases
Orchard Therapeutics, a leader in gene therapy specializing in rare diseases, has successfully secured $150 million through a Series C funding round. This substantial capital ... Read More
GlaxoSmithKline transfers rare disease gene therapy portfolio to Orchard Therapeutics in strategic deal
GlaxoSmithKline (GSK), a leading British pharmaceutical company, has entered into a significant agreement with Orchard Therapeutics, transferring its rare disease gene therapy drugs in exchange ... Read More